Sergi Barrera-Ochoa1, Nuria Vidal-Tarrason2, Eva Correa-Vázquez2, Maria Mercè Reverte-Vinaixa2, Jordi Font-Segura2, Xavier Mir-Bullo2. 1. Hand Surgery and Microsurgery Unit, ICATME-University Hospital Dexeus-Quirón, Barcelona, Spain; Orthopaedic Surgery and Traumatology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Electronic address: Dr.barreraochoa@gmail.com. 2. Hand Surgery and Microsurgery Unit, ICATME-University Hospital Dexeus-Quirón, Barcelona, Spain; Orthopaedic Surgery and Traumatology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Abstract
PURPOSE: To report outcomes after a minimum of 5 years following pyrocarbon interposition (PyroDisk) trapeziometacarpal joint implant for osteoarthritis at a single center. METHODS: We retrospectively reviewed the midterm clinical and radiological outcomes of 19 patients who had a pyrocarbon interposition implant (PyroDisk; Integra Life Sciences, Plainsboro, NJ) arthroplasty. The rate and causes of repeat surgeries, revisions, and complications were examined. RESULTS: The mean follow-up period was 68 months. Patient satisfaction was high. The mobility of the operated thumb was restored to a range of motion comparable with that of the contralateral thumb. Grip strength improved by 26%. Overall function, according to the Quick Disabilities of the Arm, Shoulder, and Hand score, showed an average improvement of 71 to 20. Pain decreased by 78% according to the numerical rating scale. Radiological evaluation using a modification of the system described by Herren revealed progression of the periprosthetic lucency (grade I-II) of the implant after 5 years in 5 of 19 (26%) patients. Progression of lucency did not predict implant loosening or failure at 5 years. Two patients had symptomatic instability that required revision. No dislocations occurred. The 5-year survival of the prosthesis was 90%. CONCLUSIONS: The PyroDisk implant for treating advanced trapeziometacarpal arthritis did not demonstrate superiority over published outcome data of trapeziectomy with or without ligament reconstruction and tendon interposition. TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic IV.
PURPOSE: To report outcomes after a minimum of 5 years following pyrocarbon interposition (PyroDisk) trapeziometacarpal joint implant for osteoarthritis at a single center. METHODS: We retrospectively reviewed the midterm clinical and radiological outcomes of 19 patients who had a pyrocarbon interposition implant (PyroDisk; Integra Life Sciences, Plainsboro, NJ) arthroplasty. The rate and causes of repeat surgeries, revisions, and complications were examined. RESULTS: The mean follow-up period was 68 months. Patient satisfaction was high. The mobility of the operated thumb was restored to a range of motion comparable with that of the contralateral thumb. Grip strength improved by 26%. Overall function, according to the Quick Disabilities of the Arm, Shoulder, and Hand score, showed an average improvement of 71 to 20. Pain decreased by 78% according to the numerical rating scale. Radiological evaluation using a modification of the system described by Herren revealed progression of the periprosthetic lucency (grade I-II) of the implant after 5 years in 5 of 19 (26%) patients. Progression of lucency did not predict implant loosening or failure at 5 years. Two patients had symptomatic instability that required revision. No dislocations occurred. The 5-year survival of the prosthesis was 90%. CONCLUSIONS: The PyroDisk implant for treating advanced trapeziometacarpal arthritis did not demonstrate superiority over published outcome data of trapeziectomy with or without ligament reconstruction and tendon interposition. TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic IV.
Authors: Francesco Smeraglia; Morena Anna Basso; Giulia Famiglietti; Andrea Cozzolino; Giovanni Balato; Alessio Bernasconi Journal: Int Orthop Date: 2022-06-08 Impact factor: 3.479
Authors: Daniel Prieto-Alhambra; Dominic Furniss; Jennifer Ce Lane; Richard Craig; Jonathan L Rees; Matthew Gardiner; Mark M Mikhail; Nicholas Riley Journal: BMJ Open Date: 2021-07-07 Impact factor: 2.692